Bioventix (LSE:BVXP) is known for returning most of its profits to shareholders, and its latest interim results continued that pattern even though Revenue fell. The diagnostics antibody specialist kept its Interim Dividend unchanged at 70p per share. How was Bioventix able to hold the payout while sales declined, and what could shape its next set of results?
An antibody supplier to diagnostics companies
Bioventix is quoted on AIM under the ticker BVXP. It develops high-affinity sheep monoclonal antibodies that are used in blood tests run on automated clinical diagnostic analysers. According to the company, its customers include "the majority of multinational clinical diagnostics companies", among them Roche, Siemens, Abbott, Beckman and Quidel-Ortho. Its income largely comes from sales of antibodies and from royalties tied to customers' sales of diagnostic tests, with its vitamin D antibody among the most established products.
The company is also developing antibodies for neurological conditions. Chief executive Peter Harrison said the value from the historic portfolio "is increasingly supplemented by the addition of new antibodies for…Alzheimer's and other neurological diseases."
What the interim results reported
On 30 March 2026, Bioventix published results for the six months ended 31 December 2025. Revenue fell to £6.16 million from £6.73 million and profit before tax declined to £4.85 million from £5.05 million. Basic Earnings Per Share were 69.38p. The board declared an interim dividend of 70p per share, unchanged from the previous year, which was paid on 24 April 2026.
Exchange rates contributed to the decline. The company said that, at constant 2024 exchange rates, revenue would have been £6.4 million and profit before tax £5.1 million. Sales of vitamin D and other core products were described as broadly in line with the prior year, while troponin antibodies performed steadily. The report noted that Siemens received US FDA approval for a revised troponin test label in November 2024.
Why the dividend could be held
The figures help explain the decision. Profit before tax of £4.85 million on revenue of £6.16 million reflects an unusually high Margin for a small company, because Bioventix has a lean cost base and much of its income comes from royalties. Cash stood at £5.3 million against £5.1 million previously, despite continued distributions. The 70p interim dividend was only slightly above basic earnings per share for the half, which suggests the board was comfortable paying out close to all of the period's earnings.
Alzheimer's progress and development
Sales of tau and neurology antibodies increased five-fold to £150,000, a small figure in group terms but a sign of growing adoption. The company said three major in-vitro diagnostics firms and three high-sensitivity platforms had incorporated its antibodies into phospho-Tau217 assay designs, and four companies were using them in total brain-derived tau assays. A collaboration with the University of Gothenburg on tau tangle pathology is expected to produce results later in 2026, and field trials of a water quality lateral flow test were planned for the second quarter of 2026.
Risks to watch
Bioventix depends on a small number of large customers and on the performance of their tests, so any loss of Market Share by a partner can affect royalties. Revenue is exposed to US dollar and euro movements. The neurology opportunity remains early, and laboratory-use assays may take years to become approved clinical products. The company's results for the year to 30 June 2026 had not been published at the time of writing.
Conclusion
Bioventix held its 70p interim dividend because its royalty-led model still produced high profit margins and growing cash, even as currency movements and lower sales reduced revenue. The company said it expected full-year trading to align with forecasts. Whether that payout pattern continues is likely to depend on core product royalties remaining stable while Alzheimer's-related antibody sales develop.
_11_18_2026_09_42_19_750506.jpg)
_11_18_2026_09_43_10_583784.jpg)




Please wait processing your request...